More on RENX

- Summary
- Chart
- Profile
- Historical


- Ratings (0.0 Score)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

RenalytixAI (NY:RENX)
Delayed: 21.19 --0 (-0%)
Prev. Close $21.19  
52 Wk High$18.34 
52 Wk Low$14.92 
Day High$21.19 
Day Low$21.19 
P/E N/A  

Friends, Peers and Foes (?): RNLX, TECH, RTNXF, DVA, AZN (more...)

May 4, 2021 02:20 PM Kantaro's COVID-SeroKlir Antibody Test Named As A Finalist For Fast Company's 2021 World Changing Ideas Awards
Apr 22, 2021 09:07 AM RenalytixAI (RENX) Announces U.S. General Services Administration Grants 10-Year Governmentwide Contract for KidneyIntelX Testing
Apr 22, 2021 07:00 AM U.S. General Services Administration Grants 10-Year Governmentwide Contract for RenalytixAI KidneyIntelX Testing
Apr 20, 2021 07:00 AM KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS)
Apr 14, 2021 07:00 AM RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform
Apr 8, 2021 07:00 AM Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions
Apr 5, 2021 07:00 AM Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure
Mar 15, 2021 07:00 AM Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics
Mar 10, 2021 10:31 AM Kantaro Biosciences Named to Fast Company's Annual List of the World's Most Innovative Companies for 2021 and Ranked First in the Joint Ventures Category
Mar 4, 2021 01:00 PM Renalytix AI plc Issue of Shares Under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights
View All Articles